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Abstract 
In an aging western population a significant number of patients continue to suffer from angina once 
all revascularization and optimal medical treatment options are exhausted. Under experimental 
conditions oral supplementation with inorganic nitrate was shown to exhibit mild blood pressure 
lowering effect, and has also been shown to promote angiogenesis, improve endothelial dysfunction 
and mitochondrial efficiency in skeletal muscle. It is unknown whether similar changes occur in 
cardiac muscle. In the current study we investigate whether oral sodium nitrate treatment will 
improve myocardial ischaemia in patients with stable angina.  
Background 
In 2013 the British Heart Foundation reported that 2.3 million patients (3.5% of the population) were 
registered with the diagnosis of angina in the United Kingdom (1). Despite impressive advances in 
revascularization options and optimal medical treatment over the last two decades, a significant 
number of patients continue to suffer from limiting angina. With improving survival and active life-
style clinicians increasingly encounter patients 10-20 years after their initial revascularization 
procedure in whom repeat revascularization is not possible or only to a limited extent. Current first 
line anti-anginal drugs are very effective, but in some patients their use can be precluded due to side 
effects (especially in pre-existing bradycardia or hypotension).  
Over the last decade inorganic nitrate (putatively via the nitrate-nitrite-nitric oxide pathway) has 
been at the centre of considerable interest as a potential therapeutic option for cardiovascular 
diseases (2,3). The human body is able to produce endogenous nitrite and nitrate via oxidation of 
nitric oxide originating from nitric oxide syntheses (NOSs). However the major source of the body 
storage pool comes from diet. Beetroot and leafy green vegetables are especially rich in inorganic 
nitrate. Inorganic nitrate is actively transported into the salivary glands and secreted into the saliva. 
Salivary bacteria reduce the nitrate into nitrite. This is in turn reduced to nitric oxide in the stomach, 
an effect which is facilitated by the presence of low pH. The nitric oxide and some of the remaining 
nitrite is absorbed in the upper small intestine and reaches all tissues via circulation presumably via 
conversion back to nitrite which is more stable. Intravenous nitrite (the main metabolite of inorganic 
nitrate) is a potent vasodilator under hypoxia, but only a modest vasodilator under normoxia (4,5).  
Nitrite reduces the increase in pulmonary arterial pressure induced by hypoxia in healthy volunteers, 
an effect which persisted even one hour after cessation of nitrite infusion when plasma levels 
returned back to the baseline (5). A single dose of oral sodium nitrate elevated angiogenic markers 
and recruited circulating angiogenic cells in healthy human volunteers (6). Improved angiogenesis 
was confirmed in an experimental animal model of chronic hind limb ischaemia following chronic 
oral supplementation (7). Recently four week supplementation with sodium nitrate resulted in 
improved endothelial dysfunction when assessed by brachial artery flow mediated vasodilation and 
also reduce arterial stiffness in an elderly population(8). A recent meta-analysis suggests that a dose 
of 300 to 600mg of sodium nitrate modestly reduces blood pressure (9). Oral inorganic nitrate 
supplementation was shown to reduce the oxygen cost of submaximal exercise in healthy volunteers  
(10-12), to improve skeletal muscle contractile function (11,13) and skeletal muscle mitochondrial 
ATP production efficiency (14).  Recently improved skeletal muscle contractile function was 
documented following a single dose of oral inorganic nitrate load (11.2 mmol beetroot juice) in 
patients suffering with systolic heart failure (15). It is unclear whether these effects in skeletal 
muscle also occur in cardiac muscle. However these vascular and myocyte properties would 
potentially be of therapeutic value in patients suffering from angina.  
Hypothesis 
The main hypothesis is to assess the effects of oral sodium nitrate treatment in patients with stable 
angina treated with background cardiovascular and anti-anginal medication. 
 
Primary outcome:  
 Time to 1mm ST depression (exercise treadmill test) 
Secondary outcomes: 
 Time to chest pain onset (exercise treadmill test) 
 Total exercise time (exercise treadmill test) 
 Angina and GTN use frequency 
 Modified Seattle Questionnaire 
 Nitrate and nitrite plasma levels, angiogenic markers 
 Dobutamine Stress Echocardiography - Tissue Doppler Imaging 
 Myocardial contractility assessment by peak systolic velocity  
Methods 
Design 
The trial has a randomised, placebo controlled, double-blind, crossover design. The study is 
approved by the Scotland A Research Ethics Committee (SAREC), subject to MHRA regulation, and 
ran in accordance with the Declaration of Helsinki. All patients will sign an informed written consent.  
Patient selection and protocol 
Patients aged 18 and over with chronic exertional angina (≥2 months duration) will be interviewed, 
examined and asked to give a written informed consent. Entry criteria will be positive ECG treadmill 
test (ETT) and either angiographic evidence of obstructive coronary artery disease or if not available 
a positive dobutamine stress echocardiogram or a positive myocardial perfusion scan. Patients will 
be screened with two modified-Bruce protocol ETTs on separate days and enrolled only if they have 
replicable exercise induced ECG evidence of ischaemia (≤15%  difference in time to 1mm ST segment 
depression at the J+80ms point between the first and the second baseline ETT (16), Figure 1.  
Exclusion criteria will be inability to perform an exercise treadmill test, women of child bearing 
potential, G6PD deficiency, LV ejection fraction <45% or New York Heart Association heart failure 
class III or IV, myocardial infarction or revascularisation within the last two months, resting ST 
depression ≥ 1mm or LBBB. Additionally patients in non-sinus rhythm and significant valvular disease 
will not included in the study as these may render the data interpretation unreliable. 
Patients will be able to continue their regular anti-anginal medication at a fixed dose apart from 
long-acting organic nitrates which will be stopped in all patients at least 72 hours prior enrollment. 
Patients undergoing a concomitant dobutamin stress echocardiogram will be asked to omit their 
beta-blocker for 48 hours prior their visits in order to facilitate the dobutamine response, unless 
clinically contraindicated in which case the beta-blocker treatment may continue uninterrupted. This 
decision will be at the discretion of the researcher (mainly depending on the severity of symptoms) 
and the elected strategy will be kept fixed throughout all subsequent patient’s visits. Patients will be 
allowed to continue short-acting sublingual GTN use and other background angina medication at a 
fixed dose. 
 
Figure 1  
Flowchart: randomised double-blind placebo controlled crossover design 
 
†
 Patient will be excluded if DSE or MPI positive but recent angiographic evidence of non-obstructive 
coronary artery disease  
Treatment and randomization process 
The trial medication will be manufactured and placed into packs containing two bottles labelled 1 
(first treatment visit) and 2 (second treatment visit) at the Western Glasgow Infirmary Pharmacy. 
Each bottle will include 14 capsules and contains either 600mg (7mmol) of sodium nitrate or placebo 
(lactose monohydrate) filled in opaque matching hard gelatin capsules. The sequence of treatment 
randomization to bottle 1 and 2 will be decided according to a list provided by Aberdeen 
Randomisation Service (CHaRT, University of Aberdeen). At no point during the study will the 
research team or the patient know which bottle contains which treatment. Following treatment 
enrollment the patient will be handed out the first bottle and start treatment with one capsule a day 
for a period of 7-10 days before undergoing a treadmill test and/or DSE and/or blood tests and a 
second bottle will be handed out. After a two weeks wash out period the second bottle will be 
started for 7-10 days and same tests performed on the last day. After each arm the patient will 
returned the bottle with the remaining capsules for compliance assessment and returned to 
pharmacy. The two weeks wash out period should be sufficient to avoid any confounding carry-over 
effects of nitrate treatment as its plasma half-life ranges from 5-8h.  
Following verbal instruction, patients will be handed-out a written diet advice sheet and asked to 
follow a low nitrate and nitrite diet, to limit caffeine intake and avoid use of anti-bacterial 
mouthwash during the treatment weeks. The latter is in order to prevent the loss of nitrate to nitrite 
bacterial bioconversion which occurs in the oral cavity and forms an integral part of the 
nitrate/nitrite entero-salivary circulation (17). On the morning of the test the patients will be asked 
to avoid any caffeine intake and take the last study capsule approximately two hours prior their visit.  
Exercise Treadmill Test 
Seventy patients will undergo an ECG treadmill test following each treatment arm. They will be 
performed approximately two hours following ingestion of the last study capsule to ensure the 
nitrate to nitrite bioconversion can take place. Automated blood pressure monitoring and 12 lead 
ECGs will be recorded at rest in standing position and during a modified Bruce protocol (at the end 
of each stage, at the time of first 1mm ST depression, at time of first chest pain onset, at peak 
exercise and every three minutes into recovery). In patients with minor resting ST depression 
(<1mm), the time to 1mm ST change will be defined as additional ST depression of 1mm below the 
resting value  as digitally displayed at J point + 80 ms(18).  
 
Dobutamine Stress Echocardiography 
All patients with a positive ECG treadmill test will be invited for a screening contrast dobutamine 
stress echocardiogram (DSE). Only patients with evidence of inducible regional wall motion 
abnormalities, satisfactory echo windows, tolerating well the baseline scan will be enrolled into the 
DSE arm. All tests will run two hours following finish of the ETT and approximately five hours 
following the last capsule ingestion (to allow optimal treatment plasma levels).  
A standard protocol will involve resting for 20 minutes, baseline acquisition, loading with 
dobutamine 10ug/kg/min for 5 minutes and then 20, 30 and 40ug/kg/min each for 3 minutes. The 
pre-defined endpoints will be: inducible regional wall motion abnormality, significant chest pain, ST 
depression >2mm or ST elevation, persistent arrhythmia and symptomatic BP fall. In patients with 
poor heart rate rise without any other predefined end-points atropine (up to total of 1.2mg) can be 
added from 30mcg/kg/min stage onwards to reach at least 85% of age predicted target HR 
(0.85*220-age)(19). LV contrast agent will be used as this was previously shown to significantly 
improve detection of inducible regional wall motion abnormalities (20). Six views (apical 4-chamber, 
2-chamber, 3-chamber, parasternal short axis at base, mid ventricle and apex) will be routinely 
obtained.  
Patients with an evidence of inducible regional wall motion abnormality on screening will be 
enrolled into the DSE arm and undergo two further tests, one following each treatment arm. These 
on-treatment DSEs will run using exactly the same individual pharmacological protocol (dobutamine 
stage ± fixed atropine dose) as defined during the patient’s screening exam. Images will be obtained 
without contrast using Doppler tissue velocity imaging (TVI, Q-stress) in apical 4-chamber, 2-
chamber and 3-chamber view only.  Image depth, width, color tissue doppler velocity scale and 
frame rate will be optimized to avoid aliasing and aim at >120 frames/s. During passively held end-
expiration three loops will be recorded in each view in the last minute of each stage. Digitized 
images will be later analyzed off line. Longitudinal basal segment peak systolic velocity (Sp) is the 
most reproducible tissue Doppler parameter, sensitive to ischaemia and related to blood flow 
(21,22). Sp will be measured in 6 segments: basal inferoseptum, basal lateral, basal inferior, basal 
anterior, basal posterior and basal anteroseptum as previously described (23). Sp will be measured 
as the maximal velocity following isovolumic contraction averaged from three cycles. 
Bloods 
Twenty patients will be invited additionally to take part in the blood subgroup. These patients will 
have blood taken on three occasions: their final screening visit and the two on-treatment visits. All 
will attend fasting from midnight, but clear water will be allowed with their morning medication.  
Patients will be advised to take the last study capsule approximately two hours prior to their study 
visit. Diabetic patients taking either tablet or insulin treatment will not be included in this substudy 
in order to avoid hypoglycemia when fasting and exercising. Blood will be taken prior to the 
treadmill test and samples for Angiogenic markers- sFlt-1, PlGF and VEGF in Li-Heparin tubes and 
nitrate/nitrite aliquots will be sampled into EDTA tubes which will supplemented with N-
Ethylmalmeide (NEM).  
Nitrite/nitrate plasma levels 
All samples will be spun immediately for 5 minutes at 1000g at room temperature, supernatant will 
be saved and snap frozen in liquid nitrogen and stored by -80°C. Nitrite/nitrate levels will be 
analyzed at the University of Southampton (27). Frozen plasma samples will be thawed in the 
presence of N-ethylmaleimide (10 mM final concentration) and deproteinized by methanol 
precipitation immediately prior to analysis. Plasma nitrite and nitrate will be measured by high-
pressure liquid ion chromatography with post-column derivatization using a dedicated analysis 
system (ENO-20 with Gilson 234 autoinjector, EPC-500 data processor and PowerChrome software; 
Eicom).  
Angiogenic markers 
Vascular endothelial growth factor (VEGF) and its receptor (VEGFR-1 = Flt-1) play a central role in 
maintaining endothelial cell integrity and in the promotion of angiogenesis and lymphogenesis. 
Soluble Flt-1 (soluble Fms-like tyrosine kinase-1 also known as soluble VEGF receptor-1 or sFlt-1)  is 
derived from  the ligand binding region of VEGFR-1/Flt-1 and its main function is believed to be in 
the regulation of VEGF bioavailability and hence suppression of VEGF signaling(28).  
Modified Seattle Questionnaire, GTN use and angina frequency 
The Seattle Questionnaire (SQ) was developed in the 1990’s as a 19-item quality of life questionnaire 
assessing five dimensions of patients suffering from angina: physical limitation, angina stability, 
angina frequency, treatment satisfaction and disease perception (37). It is widely used and was 
validated as a functional instrument in cardiovascular research outcome (38-42).  We modified the 
questionnaire to reflect the short treatment period of one week in our study when compared to the 
original SQ which in contrast interrogates over a period of the last four weeks. The higher the score 
the better is the quality of life, angina control and disease perception.  Patients will be handed out a 
checklist where they will document the frequency of their angina attacks and GTN use during their 
treatment weeks. 
Statistical analysis 
Based on data from several previous randomized controlled studies testing the efficacy of anti-
anginal medication with ECG exercise treadmill tests, the mean improvement in time to 1 mm ST 
depression between the active and placebo groups was around 50 sec [36sec with amlodipine 
(29,30), 60 sec with organic nitrates (31), 46 sec with atenolol and ranolazine (32), 46 sec with 
ivabridine(33) or 43 sec with allopurinol (16)]. The standard deviation in cross-over studies ranged 
around 80-90 sec (29,31,34,35). Projecting an expected absolute mean treatment difference 
between the two arms of 30 s and a SD of 80 sec and allowing for a significance of 0.05 at 80% 
power in a paired crossover trial design, would require a sample size of 58 patients. To allow for 
drop-outs we planned to randomize 70 patients.  
For the secondary dobutamine stress echocardiogram endpoint of tissue Doppler velocity derived 
peak systolic velocity (Sp) we aim to invite all eligible patients, but we recognize that many patients 
may not participate either due to contraindications, not tolerating the baseline scan or frequently 
their personal choice to opt out of this subgroup as the research visits will last significantly longer 
and often may interfere with their social or working life.  We will aim to recruit a minimum of twenty 
patients based on a previous study by Ingram et al who showed that  single intravenous nitrite 
infusion (30µmol NaNO2) increased peak systolic velocity  in ischaemic segments when compared to 
saline infusion (N=10, 9.5±0.5 vs 12.4±0.6cm/s, p<0.001) (Ingram, JACC 2013). A sample size of 16 
patients would be necessary to observe 1.0 cm/s velocity difference Sp and a standard deviation of 
1.0 cm/s  (two-tailed, paired, power 0.95 and p=0.05).   
The primary endpoint (time to 1mm ST-Depression) is assumed to follow a Normal distribution.  The 
analysis will follow that recommended by Senn(36)  for the analysis of a 2-treatment, 2-period cross-
over trial.  A General Linear Model (GLM) will be constructed with the following terms included: 
participant (as a random effect), period and treatment (both as fixed effects).  Baseline terms will 
not be included as baseline data is not available for both treatment periods.  Baseline data will, 
however, be tabulated and described, by randomised group (i.e. by treatment sequence). Treatment 
efficacy will be estimated as the treatment effect estimate from the GLM with a 95% confidence 
interval constructed and the hypothesis of zero effect tested (at the 5% significance level). 
Secondary endpoints will be analysed in the same manner.  For some endpoints (for example 
number of angina attack episodes), the assumption of a Normal distribution is unlikely to hold and 
an appropriate transformation will be carried out prior to analysis (for example a logarithmic or 
square-root transformation).  The residuals from each model with be check to follow and 
approximate Normal distribution. The trial statistician will conduct and report the analyses blind, i.e. 
simply comparing treatment ‘A’ to treatment ‘B’ according to the randomisation schedule provided, 
without knowing which treatment is active or placebo. All analyses will be carried out in SAS version 
9.3. 
Trial Oversight  
A Trial Steering Committee will oversee, monitored and supervised the progress of the study and will 
be responsible for the scientific integrity of the research. Data Monitoring Committee will monitor 
the safety of the study and research validity of its conduct. Research and Development department 
of the University of Aberdeen will act as the sponsor and monitor of the study.  The study is 
registered and underwent regulatory approvals by the MHRA (Medicine and Healthcare Regulatory 
Agency), NHS-Grampian R&D department and the Research Ethics Committee.  
Conclusion 
In the aging population increasing proportion of patients with advanced coronary disease survive to 
the stage when no more revascularization is possible and first line antianginal treatment options are 
exhausted.  Inorganic nitrate treatment offers via nitrate-nitrite-nitric oxide treatment pathway a 
unique anti-anginal strategy by theoretical improving selective vasodilation in hypoxic territories, 
promotion of vasodilation or improved mitochondrial efficiency. While sound in experimental animal 
studies and pilot studies on healthy volunteers, this study proposes to investigate potential anti-
anginal benefits of sodium nitrate in elderly population of patients suffering with angina and known 
advanced atherosclerotic disease who are on background poly-pharmacy. 
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